Wednesday, July 15, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

China scolds former president Donald Trump

China turned attention to former President Donald Trump’s pandemic response on Friday and advised the new administration to “learn its lesson” and stop pointing fingers at Beijing.

The pandemic put added strain on an already precarious relationship between China and the United States, and when criticized, Beijing regularly shifts the conversation back to America’s actions. Having been accused of using the pandemic to conduct information warfare, China championed its own response and pointed to the high death toll in the United States.

“As the world’s No.1 superpower, the U.S. has done much damage to the international anti-epidemic cooperation, which has made the American people and many more in the world pay a heavy price,” Chinese foreign ministry spokesperson Wang Wenbin said on Friday.

Source: Newsweek

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!